Drug interactions
Encorafenib + Pazopanib
Severity: Major
Encorafenib and Pazopanib: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Both pazopanib and encorafenib can prolong the QT interval. Combined use may increase the risk of torsades de pointes, and encorafenib's enzyme effects add some uncertainty about exposure.
What this interaction means in plain words
Encorafenib and Pazopanib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Encorafenib belongs to Oncology; Pazopanib belongs to Oncology.
Why it happens
Additive pharmacodynamic QT prolongation.
What to do
Obtain a baseline ECG and correct electrolytes. Monitor the ECG during treatment, and adjust or interrupt therapy if the QTc becomes markedly prolonged.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Encorafenib and Pazopanib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Pazopanib
- Adagrasib + Pazopanib Major
- Amiodarone + Pazopanib Major
- Amisulpride + Pazopanib Major
- Amobarbital + Pazopanib Major
- Anagrelide + Pazopanib Major
- Apalutamide + Pazopanib Major
Other interactions of Encorafenib
Frequently asked questions
Can I take Encorafenib with Pazopanib?
MediHelp rates the interaction as major. Encorafenib and Pazopanib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Both pazopanib and encorafenib can prolong the QT interval. Combined use may increase the risk of torsades de pointes, and encorafenib's enzyme effects add some uncertainty about exposure.
How serious is the interaction between Encorafenib and Pazopanib?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Obtain a baseline ECG and correct electrolytes. Monitor the ECG during treatment, and adjust or interrupt therapy if the QTc becomes markedly prolonged.
What other medicines interact with Pazopanib?
MediHelp also lists interactions of Pazopanib with, for example, Adagrasib, Amiodarone, Amisulpride. The full list is on the Pazopanib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
